Seqens

Ecully, France Founded: 2003 • Age: 23 yrs Acquired By SK Capital
Contract manufacturing services for small molecules and peptides are provided.

About Seqens

Seqens is a Healthcare company based in Ecully (France) founded in 2003, and was acquired by SK Capital in December 2021. Contract manufacturing services for small molecules and peptides are provided. The company has 39 employees. Seqens has completed 2 acquisitions, including CELLforCURE and CU Chemie Uetikon. Its website seqens.com draws about 28 thousand monthly visits. Its Indian entity Monolom India Pharma Private Limited reported revenue of β‚Ή18.17 Cr. Seqens offers products and services including APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides.

Company details

Seqens was established in 2003 in Ecully, France, as a provider of contract manufacturing services within the pharmaceutical and chemical sectors. Operations focus on the production of small molecules and peptides for clients seeking outsourced manufacturing solutions. Services encompass development, scale-up, and commercial production, with facilities supporting global supply chains. The company operates primarily from European locations, emphasizing regulatory compliance and quality standards in its processes.

Key Metrics
  • Indian entity revenue
    ₹18.17 Cr

    FY 2025 · -1% YoY

  • Indian entity net profit
    ₹2.04 Cr

    FY 2025 · 11% margin

  • Indian entity EBITDA
    ₹4.45 Cr

    FY 2025 · 24% margin

  • Investors
    Eurazeo

    & 4 more

  • Employee Count
    39
  • Investments & Acquisitions
  • Acquired by
    SK Capital

    (Dec 2021)

Products & Services of Seqens

Seqens offers a comprehensive portfolio of products and services, including APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients.

APIs and Intermediates
Pharmaceutical Products

Manufacture generic and custom active pharmaceutical ingredients for industry use.

Personal Care Ingredients
Consumer Goods

Wide range of ingredients for personal care market applications.

Custom Specialty Ingredients
Industrial Chemicals

High-quality specialized chemical products for various applications.

Apps and channels of Seqens

its YouTube channel SEQENS has 346 subscribers and 30 videos.

SEQENS
YouTube 346 subscribers 30 videos Science & Technology
Open channel

Videos from Seqens

The most watched videos on Seqens's YouTube channel, SEQENS (346 subscribers). Click a video to play it here.

CellforCure by Seqens
15.7K views
SEQENS corporate video - 20th anniversary
2K views
SEQENS builds new HPAPI Unit in Aramon (France)
1.9K views
SEQENS Lahr (Germany) - Production site for APIs and pharmaceutical intermediates
950 views

More on SEQENS.

Funding Insights of Seqens

  • Total Rounds 3
  • Investors Count 4

All 3 funding rounds of Seqens with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2017Series A–Societe Generale Capital Partenaire
–
Jun 2016Series A–Merieux Developement, Ardian
–
Jun 2016Series A––
Valuation history

5 investors in total: 5 institutional.

Investors in Seqens

Seqens has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Eurazeo, Societe Generale Capital Partenaire and Merieux Developement.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture capital investments are managed by Societe Generale Capital Partenaire.
capitalpartenaires.societegenerale.comParis, France
Private equity and debt investments are managed across multiple sectors.
1969eurazeo.comParis, France
merieux-developpement.com
Private investment firm specializing in markets and partnerships.
ardian.com
A global private investment firm focused on specialty sectors.
skcapitalpartners.comNew York, United States
Premium access

Investor details for Seqens

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Monolom India Pharma Private Limited (Seqens)

Monolom India Pharma Private Limited is the primary company behind Seqens. The board of Monolom India Pharma Private Limited currently have 4 directors; the longest-serving is Ben Zion Dolitzky, appointed in 2023. 11 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ben Zion Dolitzky
DIN 10048697
Director24 Mar 20233 yrs 7 moMonolom India Pharma Private Limited
Adrien Aymery Joel Bresson
DIN 10859851
Director22 Jan 20251 yr 9 moMonolom India Pharma Private Limited
Ashutosh Vijay Joshi
DIN 11161084
Director30 Jun 20251 yr 4 moMonolom India Pharma Private Limited
Chiara . Bergerone
DIN 10240183
DirectorMonolom India Pharma Private Limited

People of Seqens

38 people are tracked at Seqens (16 in leadership, 22 in team); the tracked headcount is 39.

NameRoleGroup
Emily C.
IT Project Manager & Business PartnerLeadership
Jean-Pierre Pilleux
Director Of OperationsLeadership
Pierre Luzeau
CEO of SEQENSLeadership
Léonard Jacquemet
Project DirectorLeadership
Emmanuelle Morandi
Head Of Europe Sales - Generic ApisLeadership
Charlie S.
Managing DirectorLeadership
Vincent Milhau
Directeur Financier / Group CFOLeadership
Laurent Castor
Vice-president Specialty IngredientsLeadership
Alexandre Gultzgoff
Group Chief Information OfficerLeadership
Paul Trouve
ISB R&d Business Partner & Head Of InfrastructureLeadership
Carole Fontaine
Operational Quality DirectorLeadership
Julien Boutet
Innovation & Biotechnology DirectorLeadership
Sophie Toussaint
Head Of StrategyLeadership
Guillaume Notheaux
R&d And Project Management BU DirectorLeadership
Victor Z.
Vice President And General Manager, Personal Care Business UnitLeadership
Cedric Ducros
Chief Procurement OfficerLeadership
Alexandra Ngawa Zenang
Business Line Manager Pharma Advanced Specialties BUTeam
Ronan Rocle
Sales & Business Development Manager CDMO Scandinavia, Eastern Europe & IsraelTeam
Allan Jensen
Commercial ManagerTeam
Lucile Balestra
Communication Manager Pharma And R&dTeam

18 more people are available in the full profile.

Premium access

Complete people profiles for Seqens

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Seqens

Figures of Monolom India Pharma Private Limited, the primary company behind Seqens, for FY 2025. Revenue was ₹18.17 Cr (-1% year on year). Net profit was ₹2.04 Cr (11% margin). EBITDA was ₹4.45 Cr (24% margin). Revenue has grown at a compounded annual rate of +5% over three years and +10% over five years.

  • ₹18.17 CrRevenue · FY 2025 · -1% YoY
  • ₹2.04 CrNet profit · 11% margin
  • ₹4.45 CrEBITDA · 24% margin
  • ₹3.44 CrPaid-up capital
  • 39Employees (provident fund records)
  • +5%Revenue CAGR, 3 years
  • +10%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Monolom India Pharma Private Limited are on its company page.

Premium access

Detailed financial statements for Seqens

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Seqens

Seqens has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CELLforCURE and CU Chemie Uetikon.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Develops innovative technologies for cell and gene therapy products to advance medical treatments.
cellforcure.comParis, France2010Jul 2023β€’β€’β€’β€’
Organic chemicals and pharmaceutical APIs are manufactured and distributed.
uetikon.comLahr, Germany1970May 2015β€’β€’β€’β€’
Premium access

Complete acquisition details for Seqens

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Seqens

6 dated milestones of Seqens across 20 years, from founding to its latest funding, stage changes and deals.

  1. Founded Seqens is founded.
  2. Acquisition Acquires CU Chemie Uetikon.
  3. Funding First funding round.
  4. Funding Latest funding round, Series A,.
  5. Exit Acquired by SK Capital.
  6. Acquisition Acquires CELLforCURE.

Web traffic of Seqens

The website of Seqens (seqens.com) receives about 28K visits a month.

  • Monthly visits
    28K

    ▲ 15.2% vs previous month

Similar websites

Websites whose visitors overlap most with Seqens. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
specchemonline.com
100%
#1,875,513View details
atamankimya.com
100%
#564,531View details
vigon.com
80%
14.8K#1,808,882View details
zehnder-systems.de
zehnder-systems.de
73%
#1,360,553–
lmt-tools.com
69%
#1,709,770View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 10 similar websites and full traffic analytics for Seqens

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Seqens

Premium access

Complete news archive for Seqens

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Seqens

Seqens was founded in 2003 and raised its 1st funding round 13 years after it was founded.

Seqens is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.

Seqens has 39 employees.

The primary company behind Seqens, Monolom India Pharma Private Limited, reported revenue of β‚Ή18.17 Cr for FY 2025, down 1% year on year.

Seqens was established in 2003 in Ecully, France, as a provider of contract manufacturing services within the pharmaceutical and chemical sectors. Operations focus on the production of small molecules and peptides for clients seeking outsourced manufacturing solutions. Services encompass development, scale-up, and commercial production, with facilities supporting global supply chains. The company operates primarily from European locations, emphasizing regulatory compliance and quality standards in its processes.

Seqens offers APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients.

Seqens has made 2 acquisitions, including CELLforCURE, and CU Chemie Uetikon.

Seqens has 5 investors. Key investors include Eurazeo, Societe Generale Capital Partenaire, Merieux Developement, Ardian, and SK Capital.

Seqens operates through Monolom India Pharma Private Limited.

Yes. Seqens was acquired by SK Capital in December 2021.

The legal entities of Seqens currently have 4 directors, including Chiara . Bergerone, Ben Zion Dolitzky, Ashutosh Vijay Joshi and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available